PHN

Sorrento Therapeutics, Inc. Appoints Former Roche Executive Tammy Reilly to the Board of Directors

Retrieved on: 
수요일, 5월 18, 2022
MBA, Laboratory, Risk, The Home Depot, Company, Pain, Private Securities Litigation Reform Act, Walmart, U.S. Securities and Exchange Commission, Patient, PHN, Vaccine, Solution, Antibody, Dermatology, Phase, Therapy, University, Marketing, Trial of the century, Oncology, Real Life, FDA, SAN, Chief commercial officer, Hoffmann-La Roche, Roche, Osteoarthritis, Forward-looking statement, Autoimmune disease, Drug development, TRPV1, RTX, Cancer, Sciatica, Trigeminal neuralgia, Security (finance), Annual report, GLOBE, Management, Pharmaceutical industry, Psychology, COVID-19, Amazon

Ms. Reilly brings more than 30 years of life science, big pharma and operating leadership experience within healthcare therapeutics, consumer merchandising and healthcare diagnostic companies to Sorrento.

Key Points: 
  • Ms. Reilly brings more than 30 years of life science, big pharma and operating leadership experience within healthcare therapeutics, consumer merchandising and healthcare diagnostic companies to Sorrento.
  • Sorrento continues to strengthen its already experienced board of directors, said Henry Ji, Ph.D., Chairman and Chief Executive Officer of Sorrento.
  • We are excited to welcome Tammy who is a proven executive and entrepreneur.
  • Tammy brings deep business and operating experience in innovative therapeutics, consumer merchandising and diagnostics, which will complement the existing capabilities of our board in several key areas.

Sorrento’s License Partner, Lee’s Pharm, Announces Full Enrollment of 498 Patients in a Phase III Trial of Socazolimab (Anti-PD-L1 Antibody) for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)

Retrieved on: 
화요일, 5월 17, 2022
U.S. Securities and Exchange Commission, Carboplatin, Dermatology, Antibody, Review, Center, Autoimmune disease, Cholangiocarcinoma, Risk, NDA, TRPV1, Private Securities Litigation Reform Act, Cancer, Annual report, Squamous cell carcinoma, Pain, Phase, Therapy, Clinical trial, Degenerative disease, Marketing, SAN, Obstetrics, Osteoarthritis, GLOBE, Death, Company, Survival, Postherpetic neuralgia, Vaccine, Pharming, Health, Trial of the century, FDA, COF, Human, Ovarian cancer, Maintenance, RTX, Sciatica, Security (finance), Etoposide, Patient, PHN, PD-1, ADA, Forward-looking statement, NMPA, Glioblastoma, Safety, Drug development, ADCC, Pharmaceutical industry, Fine chemical, Generic drug, COVID-19

COF has completed the patient enrollment (498 patients) for a Phase III, multicenter, randomized, double blinded, placebo-controlled clinical trial of Socazolimab combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC).

Key Points: 
  • COF has completed the patient enrollment (498 patients) for a Phase III, multicenter, randomized, double blinded, placebo-controlled clinical trial of Socazolimab combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC).
  • Socazolimab is an in-licensed product from Sorrento for the Peoples Republic of China, Hong Kong, Macau and Taiwan.
  • RTX has been cleared for a Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients.
  • ZTlido is a registered trademark owned by Scilex Pharmaceuticals Inc.
    All other trademarks are the property of their respective owners.

Sorrento Announces FDA Authorization to Proceed With Phase 2 Study of Abivertinib (Fujovee™) to Treat Metastatic Castrate Resistant Prostate Cancer (MAVERICK Trial)

Retrieved on: 
화요일, 5월 17, 2022
Phenotype, CRPC, BTK, Pain, Risk, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Postherpetic neuralgia, TKI, SNP, Patient, RPF, PHN, Vaccine, Antibody, Bone, RECIST, Phase, Therapy, MCRPC, Trial of the century, FDA, SAN, IND, Partnership, Prostate cancer, Toxicity, Osteoarthritis, Autoimmune disease, Safety, Forward-looking statement, HSD3B1, EGFR, TRPV1, Phosphorylation, CAGR, RTX, Cancer, Castration, Sciatica, Security (finance), Neoplasm, Annual report, GLOBE, Pharmaceutical industry, Pet, Generic drug, COVID-19

FDA granted IND clearance for Abivertinib (Fujovee) for the Phase 2 MAVERICK study to be conducted in participants with metastatic castrate resistant prostate cancer (mCRPC) at multiple centers in the United States.

Key Points: 
  • FDA granted IND clearance for Abivertinib (Fujovee) for the Phase 2 MAVERICK study to be conducted in participants with metastatic castrate resistant prostate cancer (mCRPC) at multiple centers in the United States.
  • The MAVERICK study will be conducted in a partnership with the Prostate Cancer Clinical Trials Consortium and will enroll participants with both abiraterone-nave and abiraterone-progressing mCRPC.
  • Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19.
  • RTX has been cleared for a Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients.

The Passive House Network Announces Buildings Tour for Boston Conference

Retrieved on: 
월요일, 5월 16, 2022
SF, Architecture, Passive house, Education, Knowledge, PHI, Winthrop Center, TAT, Goal, PHN, Motivation, House, Loop, MP, Research, Heat, Ventilation, Conference, Ross House Association, Hospital, Music Builds Tour, Mattapan station, The Tour, Lists of schools in England, Handel Architects, Interior design, Heating, ventilation, and air conditioning, Communications satellite

BOSTON, May 16, 2022 /PRNewswire-PRWeb/ -- The Passive House Network announces the Conference Passive House Buildings Tour for Passive House 2022 Conference: Passive House For All. The Tour will take place on June 18.

Key Points: 
  • The Buildings Tour is a great way to see Passive House in-action, hear directly from the professionals with their work, and make new Passive House friends along the way.
  • BOSTON, May 16, 2022 /PRNewswire-PRWeb/ -- The Passive House Network announces the Conference Passive House Buildings Tour for Passive House 2022 Conference: Passive House For All .
  • The Passive House Network (PHN), formerly known as NAPHN, is a 501(c)3 that provides Passive House high-performance building education and resources to professionals across the U.S. that transform how they think and work with buildings.
  • http://www.passivehouse.com | http://www.passipedia.org
    The International Passive House Association is a membership, communications, and global community-building arm of the Passive House Institute with over 30 affiliated regional Passive House organizations around the world.

Scilex, a Sorrento Company, Highlights Safety Data From Phase 1 Trial of SP-104, a Proprietary Low Dose Naltrexone for Fibromyalgia

Retrieved on: 
수요일, 5월 11, 2022
Sciatica, PALO, Failure, Safety, Dexamethasone, Anxiety, Quality of life, PHN, BCA, TRPV1, SEC, Technology, Combination company, Risk, Phase, Antibody, Stomach, Forward-looking statement, Postherpetic neuralgia, Pain, Company, Securities Act of 1933, Patient, Fast track (FDA), Naltrexone, Prospectus, Physician, FDA, RTX, Regulation of tobacco by the U.S. Food and Drug Administration, Nasdaq, SAN, Therapy, Capsule, Population, Private Securities Litigation Reform Act, Volunteering, Low back pain, Fibromyalgia, Time, Autoimmune disease, Hyperalgesia, NCT, Radiculopathy, Vaccine, Sale, FM, SP-104, Common, Acquisition, COVID-19, Sleep, Name, GLOBE, Form, Food, Combined, Proxy, Dysphoria, Cancer, Osteoarthritis, SP-102, Pharmacy, Chronic pain, Insomnia, Pharmaceutical industry, Security (finance)

SP-104 is a novel, proprietary, fixed dose, delayed burst release of low dose naltrexone hydrochloride, 4.5 mg, for treatment of fibromyalgia (FM).

Key Points: 
  • SP-104 is a novel, proprietary, fixed dose, delayed burst release of low dose naltrexone hydrochloride, 4.5 mg, for treatment of fibromyalgia (FM).
  • Prior investigational trials support the use and development of SP-104, delayed burst release naltrexone hydrochloride 4.5 mg, for FM.
  • Physicians currently use the commercially available high-dose tablets (naltrexone hydrochloride 50 mg) and have compounding pharmacies aliquot lower doses for patients.
  • RTX has been cleared for a Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients.

National Nurses Week Events at University of Phoenix Feature College of Nursing Dean Raelene Brooks

Retrieved on: 
월요일, 5월 9, 2022
Nursing, Education, Health, General Health, Other Education, Continuing, University, Magnet, COVID-19, National Nurses United, Global health, University, Culture, American Association of Colleges of Nursing, Student, Riverside, RN, MSN, Workforce, National League for Nursing, Equifax Workforce Solutions, National League, Critical care nursing, Trauma, University of Phoenix, Careers New Zealand, Association, American Association, Human voice, Knowledge, PHN, Lead, Critical care, Science, Phoenix College, Brooks, Ohio Valley Medical Center, Medicine, Hospital, Nursing

The University of Phoenix College of Nursing Dean Raelene Brooks, Ph.D., RN, led a panel event hosted by the universitys Southern California Campus on Saturday, May 7, in collaboration with the universitys Workforce Solutions team.

Key Points: 
  • The University of Phoenix College of Nursing Dean Raelene Brooks, Ph.D., RN, led a panel event hosted by the universitys Southern California Campus on Saturday, May 7, in collaboration with the universitys Workforce Solutions team.
  • National Nurses Week is an opportunity to bring more visibility to nurses for their leadership abilities, their highly specialized knowledge and critical thinking skills - and their compassion, shares Brooks.
  • University of Phoenix supports and celebrates the tired and tireless efforts of our nations nurses at this event.
  • She is a Doris Howell Scholar and an active member of several professional nursing associations including American Association of Colleges of Nursing, National League of Nursing, and Association for Critical Care Nursing.

Independence Blue Cross announces winners and finalists of its 4th Annual Celebrate Caring campaign honoring outstanding nurses

Retrieved on: 
월요일, 5월 9, 2022
Blue Cross Blue Shield Association, APRN, Health literacy, Independence Blue Cross, Mental disorder, PHN, Friends, NAMI, Nursing, National Multiple Sclerosis Society, Twitter, Grief, Patient, NICU, National Multiple Sclerosis Society, National Capital Chapter, Family, Hospital, Nemours Children's Hospital, LinkedIn, Mental health, Blue, National Alliance, Instagram, MSN, CME, Angel Gardens, Pregnancy, Sears, Infant, Celebrate, Homelessness, Public health, Mentorship, COVID-19, Parent, IHeartRadio, National Alliance on Mental Illness, Company, Health equity, Hospice, Organization, Blue Cross, Health, Independence Blue Cross Foundation, Vaccination, DNP, Virtua, Case management (US healthcare system), Medicine, Pharmaceutical industry, Independence, Facebook

PHILADELPHIA, May 9, 2022 /PRNewswire/ -- During National Nurses Week (May 6 12), Independence Blue Cross (Independence) is proud to announce the winners and finalists of its fourth annual Celebrate Caring campaign that honors extraordinary nurses in the Philadelphia region.

Key Points: 
  • PHILADELPHIA, May 9, 2022 /PRNewswire/ -- During National Nurses Week (May 6 12), Independence Blue Cross (Independence) is proud to announce the winners and finalists of its fourth annual Celebrate Caring campaign that honors extraordinary nurses in the Philadelphia region.
  • Independence annually celebrates nurses who demonstrate superior care and compassion to their patients and communities.
  • And as a thank you, winners will receive a gift card and enjoy dinner for two and a night's stay in Atlantic City.
  • Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.

The Passive House Network Announces Program for National Building Conference Focused on Integrated Climate Action

Retrieved on: 
월요일, 5월 9, 2022
Carbon, Ross House Association, New Frontier, University, PHI, Policy, House, Education, Heat, Winthrop Center, Program, Ventilation, Equity, Industry, Knowledge, Hospital, University of Southern Maine, Power-added efficiency, Passive house, Efficiency, PHN, Intention, Equitable, Public health, Conference, Goal, Research, Primary, Awareness, Renewable energy, Management, Animal, Communications satellite, Heating, ventilation, and air conditioning

BOSTON, May 9, 2022 /PRNewswire-PRWeb/ -- The Passive House Network announced the full program today for the Passive House 2022 Conference: Passive House For All. The conference will take place on June 10 online and on June 17 in-person in Boston, and online.

Key Points: 
  • BOSTON, May 9, 2022 /PRNewswire-PRWeb/ -- The Passive House Network announced the full program today for the Passive House 2022 Conference: Passive House For All.
  • The event will take on the full range of specialized technical, process, and policy aspects of Passive House that drives climate action.
  • Primary event partners include The Passive House Institute (PHI), the global leader of Passive House research, as well as the regional group, Passive House Massachusetts (PHMA).
  • http://www.passivehouse.com http://www.passipedia.org
    The International Passive House Association is a membership, communications, and global community-building arm of the Passive House Institute with over 30 affiliated regional Passive House organizations around the world.

Quicker and Less Expensive Path to Degrees and Career Advancement for Nurses Opened Up by Partnership between National University and Palomar College

Retrieved on: 
수요일, 5월 4, 2022
NU, National university, PMHNP, Student, FNP, BSN, RN, MSN, Master of Science in Nursing, Time, Certification, Partnership, Program, MHNP, Education, Family nurse practitioner, Palomar College, Adult, Learning, PHN, Psychiatric-mental health nurse practitioner, KwaMashu, Goal, SAN, RNS, Medicine, Science, Nursing

SAN DIEGO, May 4, 2022 /PRNewswire-PRWeb/ -- National University and Palomar College have partnered to create a new path for nursing students and professional nurses to more quickly earn advanced nursing degrees, save money on their education costs, and position themselves for better career opportunities after graduation.

Key Points: 
  • "Working with Palomar College, we are able to create a clear and quick pathway for students and working nurses toward better opportunities and greater contributions."
  • Starting in June of 2022, there will be an exclusively online RN-BSN cohort for RN Palomar College students and alumni.
  • About Palomar College: Palomar College is a public two-year community college.
  • A National University office is located on the second floor at the Palomar College, Rancho Bernardo location.

Levena Biopharma, A Sorrento Company, Announces Positive Clinical Data for Its Out-Licensed A166 Product Candidate, A Third-Generation Anti-HER2-ADC, In Treating Heavily Pretreated HER2-Positive Breast Cancer Patients

Retrieved on: 
화요일, 5월 3, 2022
Antibody, U.S. Securities and Exchange Commission, Sciatica, ADC, Society, Phase, Forward-looking statement, Private Securities Litigation Reform Act, PFS, Pain, GLOBE, Conjugation, Antibody-drug conjugate, Safety, Patient, Autoimmune disease, Security (finance), Trial of the century, Risk, Kensington Security Slot, RTX, FDA, CSCO, Cancer, HER2/neu, Annual report, Trastuzumab emtansine, Osteoarthritis, Progression-free survival, Vaccine, Trigeminal neuralgia, PHN, Kelun, Conference, TRPV1, SAN, ORR, Therapy, Fine chemical, Pharmaceutical industry, COVID-19

A166 has demonstrated promising antitumor activity with clinically meaningful responses in heavily pretreated subjects with HER2-positive breast cancer.

Key Points: 
  • A166 has demonstrated promising antitumor activity with clinically meaningful responses in heavily pretreated subjects with HER2-positive breast cancer.
  • Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19.
  • Program for SEMDEXA, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022.
  • Forward-looking statements include statements regarding A166 (Anti-HER@-ADC); the therapeutic and clinical potential of A166, including its antitumor activity; the potential safety and efficacy of A166 and the clinical testing of A166.